(image: Philips International B.V.)
Amsterdam, the Netherlands, May 19 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its newest solution for precision diagnosis with the global introduction of its spectral detector-based Spectral Computed Tomography (CT) 7500. This latest intelligent system delivers high quality spectral images for every patient on every scan 100% of the time to help improve disease characterization, and reduce rescans and follow-ups, all at the same dose levels as conventional scans. The time-saving spectral workflow is fully integrated, enabling the technologist to get the patient on and off the table quickly – spectral chest scans and head scans take less than one second, and a full upper body spectral scan can be completed in less than two seconds – while still delivering high quality imaging that allows the physician to rapidly deliver a confident diagnosis and effective treatment plan for each patient.
Human and financial cost of misdiagnosis
Missed and delayed diagnoses contribute to roughly 10% of patient deaths annually [1], while an estimated 10-20% of all medical diagnoses are inaccurate [2]. The financial costs resulting from unnecessary, suboptimal and repeat imaging costs as much as $12 Billion USD annually [3]. The new Spectral CT 7500 was designed for first-time-right diagnosis and has demonstrated a 34% reduction in time to diagnosis, a 25% reduction in repeat scans and a 30% reduction in follow-up scans [4].
“With such great human and financial costs due to misdiagnosis, Spectral CT 7500 sets a new standard of care where image quality, dose and workflow come together to deliver valuable clinical insights. This latest intelligent system helps to bring clarity to defining moments in healthcare by delivering on certainty, simplicity and reliability in every clinical area from cardiac care, to emergency radiology, diagnostic oncology, intervention and radiation oncology,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “Our detector-based spectral technology ensures spectral data is always available and is seamlessly integrated into current workflows, meaning scans are fast, and clinicians are able to send patients the right treatment pathway with a more confident diagnosis.”
Spectral CT has demonstrated a higher sensitivity in detecting malignant findings and has improved readings of incidental findings [5] [6]. With Philips spectral detector CT, photons add more value by helping salvage sub-optimal injection scans without the need to re-scan the patients, shortening the time to diagnosis.
“We rely on CT scans to provide us valuable insights. But conventional CT scanners are limited and can only show us where things are located – like lesions, cysts, bleeds, fractures and more. Philips spectral detector-based systems help to characterize what the finding is, not just where it is, providing us greater confidence in diagnoses,” said Dr. Finn Rasmussen, Associate Professor, Consultant Radiologist, MD, DMSc at Aarhus University. “We have seen significant reductions in rescans and follow-ups by adopting spectral into our workflow for faster and more accurate diagnosis [7].”
Expanded patient populations and optimized workflows
Spectral CT 7500 expands on Philips proven spectral-detector benefits to now include additional patient populations that were not previously served. The spectral insights are available for all patients, from pediatric to bariatric, and for any clinical indication, including challenging cardiac scans with high and irregular heart rates, without compromising image quality, dose or workflow. The spectral workflow enables radiologists to optimize reading with rich spectral results and AI-based smart tools available in any reading environment with Spectral Magic Glass on PACS.
Visit Philips Spectral CT 7500 for more information, including access to an on-demand virtual round table discussion with Philips executives and industry leaders discussing this latest innovation.
[1] https://pubmed.ncbi.nlm.nih.gov/23011708/
[2] https://www.coverys.com/About-Us/Foundation/Grants-For-Improving-Diagnostic-Accuracy
[3] https://reactiondata.com/wp-content/uploads/2015/02/peer60:unnecessaryimaging.pdf
[4] Analysis by CARTI Cancer Center in Little Rock Arkansas and University Hospitals of Cleveland – Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[5] Analysis by Aarhus University Hospital Aarhus, Denmark. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[6] Analysis by University Hospital Cleveland, USA. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[7] Results from case studies are not predictive of results in other cases. Results in other cases may vary.
For further information, please contact:
Kathy O’Reilly
Philips Global Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Spectral CT Side View
- Spectral CT 7500 Motion in Right Coronary Artery Comparison
- Spectral CT 7500 Myocardial Perfusion Comparison
- Spectral CT 7500 Pancreatic Lesion Comparison
Source: Philips International B.V. via GLOBE NEWSWIRE
